Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations
Sandoz (OTCQX:SDZNY), a global leader in generic and biosimilar medicines, has announced a significant 10-year virtual Power Purchase Agreement (PPA) with Elawan Energy for new solar projects in Spain. The partnership will develop 150 MW solar projects in Valladolid, Castilla y León, which will cover nearly 90% of electricity demand for Sandoz's European operations.
The agreement represents a major step in Sandoz's decarbonization strategy, building upon similar PPAs across multiple production sites. The company has also submitted a Commitment Letter to the Science Based Targets Initiative (SBTi), pledging to set science-based carbon emission reduction targets by January 2026.
Sandoz (OTCQX:SDZNY), leader globale nei medicinali generici e biosimilari, ha annunciato un importante accordo virtuale di acquisto di energia (PPA) della durata di 10 anni con Elawan Energy per nuovi progetti solari in Spagna. La partnership svilupperà 150 MW di impianti solari a Valladolid, Castilla y León, che copriranno quasi il 90% del fabbisogno elettrico delle attività europee di Sandoz.
L'accordo rappresenta un passo decisivo nella strategia di decarbonizzazione di Sandoz, rafforzando iniziative simili già avviate in diversi siti produttivi. L'azienda ha inoltre inviato una lettera di impegno alla Science Based Targets Initiative (SBTi), impegnandosi a definire obiettivi di riduzione delle emissioni basati sulla scienza entro gennaio 2026.
Sandoz (OTCQX:SDZNY), líder mundial en medicamentos genéricos y biosimilares, ha anunciado un importante PPA virtual de 10 años con Elawan Energy para nuevos proyectos solares en España. La alianza desarrollará 150 MW de energía solar en Valladolid, Castilla y León, que cubrirán casi el 90% de la demanda eléctrica de las operaciones europeas de Sandoz.
El acuerdo supone un avance significativo en la estrategia de descarbonización de Sandoz, apoyándose en PPAs similares en varios centros de producción. La compañía también ha presentado una carta de compromiso a la Science Based Targets Initiative (SBTi), comprometiéndose a establecer objetivos científicos de reducción de emisiones antes de enero de 2026.
Sandoz (OTCQX:SDZNY)는 제네릭 및 바이오시밀러 의약품 분야의 글로벌 선두주자로서 스페인에서의 신규 태양광 프로젝트를 위해 Elawan Energy와 10년짜리 가상 전력구매계약(PPA)을 체결했다고 발표했습니다. 이번 파트너십은 바야돌리드(Valladolid, Castilla y León)에 150MW 규모의 태양광 사업을 개발해 Sandoz의 유럽 사업 전력 수요의 약 90%에 달하는 전력을 공급할 예정입니다.
이 계약은 여러 생산 현장에서 체결한 유사한 PPA를 기반으로 한 Sandoz의 탈탄소화 전략에 있어 중요한 진전입니다. 회사는 또한 Science Based Targets Initiative(SBTi)에 서약서(Commitment Letter)를 제출하여 2026년 1월까지 과학 기반의 탄소 배출 감축 목표를 설정하겠다고 약속했습니다.
Sandoz (OTCQX:SDZNY), leader mondial des médicaments génériques et biosimilaires, a annoncé un important accord virtuel d'achat d'électricité (PPA) sur 10 ans avec Elawan Energy pour de nouveaux projets solaires en Espagne. Le partenariat développera 150 MW de projets solaires à Valladolid, Castille-et-León, qui couvriront près de 90 % de la demande électrique des activités européennes de Sandoz.
Cet accord constitue une étape majeure dans la stratégie de décarbonation de Sandoz, s'appuyant sur des PPA similaires conclus sur plusieurs sites de production. L'entreprise a également soumis une lettre d'engagement à la Science Based Targets Initiative (SBTi), s'engageant à définir des objectifs de réduction des émissions fondés sur la science d'ici janvier 2026.
Sandoz (OTCQX:SDZNY), ein weltweit führendes Unternehmen für Generika und Biosimilars, hat einen bedeutenden zehnjährigen virtuellen Stromabnahmevertrag (PPA) mit Elawan Energy für neue Solarprojekte in Spanien angekündigt. Die Partnerschaft wird 150 MW an Solarprojekten in Valladolid, Kastilien und León entwickeln, die fast 90 % des Strombedarfs der europäischen Aktivitäten von Sandoz abdecken sollen.
Die Vereinbarung ist ein wichtiger Schritt in der Dekarbonisierungsstrategie von Sandoz und baut auf ähnlichen PPAs an mehreren Produktionsstandorten auf. Das Unternehmen hat außerdem eine Verpflichtungserklärung (Commitment Letter) an die Science Based Targets Initiative (SBTi) eingereicht und sich verpflichtet, bis Januar 2026 wissenschaftlich fundierte Minderungsziele für Emissionen festzulegen.
- Agreement will cover nearly 90% of electricity demand for European operations
- Significant renewable energy commitment with 150 MW solar project capacity
- 10-year long-term partnership demonstrates strong commitment to sustainability
- Formal commitment to Science Based Targets Initiative (SBTi) for carbon reduction
- None.
MEDIA RELEASE
- Sandoz signs 10-year virtual PPA with Elawan Energy for new 150 MW solar projects in Spain
- Will cover nearly
90% of electricity demand for European operations - Concrete step to support global Sandoz decarbonization efforts and sustainability commitment
Basel, August 12, 2025 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced the signing of a 10-year virtual Power Purchase Agreement (PPA) with Elawan Energy, a global player in the renewable energy sector, for new-build solar projects in Valladolid, Castilla y León, Spain. This agreement marks a concrete step in the company’s decarbonization strategy, reinforcing its commitment to climate action and sustainable operations.
Europe is home to the majority of Sandoz operations, and this partnership is expected to meet nearly
Glenn Gerecke, Chief Manufacturing and Supply Officer, said: “At Sandoz, environmental sustainability is a core part of how we operate – reflecting our responsibility to both the planet and our people. Our collaboration with Elawan Energy to develop this new solar project in Spain marks a concrete step toward decarbonizing our operations. By covering nearly
This new partnership contributes to Sandoz ongoing efforts to decarbonize electricity use globally, complementing similar Power Purchase Agreements for production operations across multiple sites. In a broader context, Sandoz announced in 2024 the formal submission of a Commitment Letter to the Science Based Targets Initiative (SBTi), confirming the company’s intent to set science-based carbon emission reduction targets. Sandoz has committed to submitting its plan to SBTi for validation by the end of January 2026.
Picture material
Please find here the download link to the image material.
DISCLAIMER
This Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly revise any forward-looking statements, except as required by law.
ABOUT SANDOZ
Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure 900 million patient treatments are provided by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,300 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the world’s first biosimilar in 2006. In 2024, Sandoz recorded net sales of USD 10.4 billion.
CONTACTS
| Global Media Relations contacts | Investor Relations contacts |
| Global.MediaRelations@sandoz.com | Investor.Relations@sandoz.com |
| Alex Kalomparis +41 792 790285 | Craig Marks +44 7818 942 383 |
| Joerg E. Allgaeuer +49 171 838 4838 | Rupreet Sandhu +41 79 410 5472 |
Attachment
FAQ
What is the size of Sandoz's new solar energy agreement with Elawan Energy?
How much of Sandoz's European electricity demand will the new solar project cover?
Where will Sandoz's new solar projects be located?
What are Sandoz's commitments to the Science Based Targets Initiative (SBTi)?
Who is Sandoz partnering with for this renewable energy initiative?
